Filings & Shareholder Info

Investor Relations

SEC Filings

As of July 31, 2022, Briacell determined that it no longer qualified as a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act. This means that, as of August 1, 2022, the Company has been required to comply with all of the periodic disclosure requirements of the Securities Exchange Act of 1934 applicable to U.S. domestic issuers, such as Forms 10-K, 10-Q and 8-K, rather than the forms the Company has filed with the Securities and Exchange Commission (“SEC”) in the past, as a foreign private issuer, such as Forms 40-F and 6-K. Accordingly, the Company is now required to prepare its financial statements filed with the SEC in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

AGM 2024

SEDAR+ Filings

For additional SEDAR Filings, please visit https://www.sedarplus.ca/

Shareholder Information

Transfer Agent & Registrar

Computershare Investor Services

100 University Ave., 8th Floor, North Tower
Toronto, ON M5J 2Y1, Canada

1-800-564-6253 (Toll free in Canada & the US)
514-982-7555 (International direct dial)

Fax: 1-888-453-0330

www.computershare.com/service

CUSIP

BriaCell Therapeutics Corp. Common Shares
CUSIP: 107930109
ISIN: CA1079301091

BriaPro Therapeutics Common Shares (privately held)
CUSIP:107931107
ISIN: CA1079311074

BCTXW (NASDAQ)
CUSIP Number: 107930109
ISIN: CA1079301091